Anthera Pharmaceuticals Inc
OTC:ANTH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Getin Holding SA
WSE:GTN
|
PL |
|
S
|
Sun Life Financial Inc
NYSE:SLF
|
CA |
|
N
|
Nueva Expresion Textil SA
LSE:0R6G
|
ES |
|
S
|
Smurfit Kappa Group PLC
LSE:SKG
|
IE |
|
Societe Industrielle et Financiere de l'Artois SA
PAR:ARTO
|
FR |
|
Nissin Foods Co Ltd
HKEX:1475
|
HK |
|
S
|
Supreme Infrastructure India Ltd
NSE:SUPREMEINF
|
IN |
|
LPKF Laser & Electronics AG
XETRA:LPK
|
DE |
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
IN |
|
360 Security Technology Inc
SSE:601360
|
CN |
|
T
|
Torunlar Gayrimenkul Yatirim Ortakligi AS
IST:TRGYO.E
|
TR |
Anthera Pharmaceuticals Inc
Total Current Assets
Anthera Pharmaceuticals Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Anthera Pharmaceuticals Inc
OTC:ANTH
|
Total Current Assets
$8.7m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Assets
$29.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
6%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Assets
$18.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Assets
$29.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Assets
$11.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Assets
$18B
|
CAGR 3-Years
4%
|
CAGR 5-Years
13%
|
CAGR 10-Years
20%
|
|
Anthera Pharmaceuticals Inc
Glance View
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life threatening diseases. The company is headquartered in Hayward, California and currently employs 21 full-time employees. The company went IPO on 2010-03-02. The firm has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.
See Also
What is Anthera Pharmaceuticals Inc's Total Current Assets?
Total Current Assets
8.7m
USD
Based on the financial report for Mar 31, 2018, Anthera Pharmaceuticals Inc's Total Current Assets amounts to 8.7m USD.
What is Anthera Pharmaceuticals Inc's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
-31%
Over the last year, the Total Current Assets growth was -62%. The average annual Total Current Assets growth rates for Anthera Pharmaceuticals Inc have been -41% over the past three years , -31% over the past five years .
